|
Filgrastim
|
DB00099 |
[Chemotherapy-induced neutropenia (CIN) is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality and can increase the cost of cancer therapy. In these cases, colony stimulating factor is necessary to restore important cells for immune function [A35591].
For over twenty years, granulocyte colony-stimulating factors (G-CSFs; filgrastims) have been a pillar of treatment and prevention of CIN, and have been found to reduce the risk of neutropenia across various patient settings, decrease the incidence of febrile neutropenia, reduce the incidence of infection, reduce the requirement for treatment with antibiotics, and accelerate neutrophil recovery [A35591].
Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analog. It is marketed as the brand name _Neupogen_ by Amgen (initially approved in 1998) and as _Nivestym_, a biosimilar agent by Pfizer. Nivestym was approved by the FDA on July 20th, 2018 [L3735]. Between 1998 and the present, Neupogen/filgrastim has been approved for various indications [L3744].
_Tbo-filgrastim_, which is marketed by Sicor Biotech and FDA approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting [F719]. On March 6, 2015, the FDA approved the biosimilar Zarxio (filgrastim-sndz) and is indicated for use in the same conditions as Neupogen. Zarxio is marketed by Sandoz [L3742].] |
|
Vanillyl alcohol
|
DB12087 |
[Vanillyl alcohol has been used in trials studying the treatment of Smoking.] |
|
TT-232
|
DB12088 |
[Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).] |
|
Lorvotuzumab mertansine
|
DB12089 |
[Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.] |
|
Mafosfamide
|
DB12083 |
[Mafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.] |
|
ADP-597
|
DB12084 |
[JNJ-38431055 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.] |
|
LCL-161
|
DB12085 |
[LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.] |
|
Oxitropium
|
DB12086 |
[Oxitropium has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.] |
|
Ritobegron
|
DB12080 |
[Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers).] |
|
Anecortave
|
DB12081 |
[Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).] |
|
Vesnarinone
|
DB12082 |
[Vesnarinone has been used in trials studying the treatment of HIV Infections and Sarcoma, Kaposi.] |
|
Pentyl Trihydrogen Diphosphate
|
DB02707 |
|
|
6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine
|
DB02705 |
|
|
Mercaptocarboxylate Inhibitor
|
DB02706 |
|
|
Fusidic acid
|
DB02703 |
[An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.] |
|
(2R,3R,4R,5R)-3,4-Dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2,5-bis(2-phenylethyl)hexanediamide
|
DB02704 |
|
|
Nicotinamide
|
DB02701 |
[An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.] |
|
XV638
|
DB02702 |
|
|
3-Deoxy-D-Glucosamine
|
DB02700 |
|
|
Pseudouridine-5'-Monophosphate
|
DB03829 |
|
